Abstract Number: 0601 • ACR Convergence 2020
The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases
Background/Purpose: Persistence on therapy is an important consideration in rheumatic diseases. There are multiple treatment options that influence long term disease management and a better…Abstract Number: 0829 • ACR Convergence 2020
International Comparison of Japanese and US Cross Country Utilization of RA Medications
Background/Purpose: Little is known regarding differences in DMARD utilization across countries. A better understanding is needed to contextualize findings from different countries.1 Using the same…Abstract Number: 1041 • ACR Convergence 2020
Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center
Background/Purpose: Non-Infectious Ocular inflammatory disease (OID) is a group of immune-mediated diseases involving the ocular surface, uveal tract, retina, optic nerve, and peri-orbital tissue. Patients…Abstract Number: 1493 • ACR Convergence 2020
Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis
Background/Purpose: Treatment response in JIA is often viewed as a binary outcome: response or non-response, usually assessed using composite, multidimensional measures, such as the juvenile…Abstract Number: 1774 • ACR Convergence 2020
Making Decisions About Medication Use, Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Grounded Theory Study
Background/Purpose: Despite guidelines for managing rheumatoid arthritis (RA) in pregnancy, high rates of discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) considered safe for women with RA…Abstract Number: 0009 • ACR Convergence 2020
Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases
Background/Purpose: Antimalarial drugs (ADs), including chloroquine (CQ) and hydroxychloroquine (HCQ), have anti-inflammatory, immunomodulatory, antiparasitic, anti-thrombotic, and antiviral properties. Their indications in rheumatology have been known…Abstract Number: 0239 • ACR Convergence 2020
Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials
Background/Purpose: Filgotinib (FIL)—an oral, selective Janus kinase 1 inhibitor (JAKi)—improved RA signs and symptoms in three phase 3 trials. Despite the efficacy of FIL and…Abstract Number: 0607 • ACR Convergence 2020
The Evolution of Rheumatologist’s Practice in Response to the COVID19 Pandemic
Background/Purpose: The COVID19 pandemic was a turning point for Rheumatology. This survey of rheumatologists (rheums) assessed its impact on care delivery, patient counseling and drug…Abstract Number: 0830 • ACR Convergence 2020
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…Abstract Number: 1047 • ACR Convergence 2020
Prospective Analysis of a Cohort of Patients with Interstitial Lung Disease Associated with Connective Tissue Disease and Their Response to Immunosuppression with Mycophenolate Mofetil and Rituximab
Background/Purpose: Connective tissue diseases (CTDs) are commonly identified causes for interstitial lung disease (ILD). Compared with idiopathic interstitial pneumonias, patients with CTD-ILD and interstitial pneumonia…Abstract Number: 1495 • ACR Convergence 2020
Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. We report the safety, tolerability, and efficacy of tofacitinib in patients (pts)…Abstract Number: 1776 • ACR Convergence 2020
Safety and Beneficial Effects of Hydroxychloroquine on Pregnancy Outcomes in Women with Systemic Lupus Erythematosus
Background/Purpose: The use of hydroxychloroquine (HCQ) has long been established in Systemic Lupus Erythematosus(SLE) and especially as applicable drug during pregnancy. Recently, beneficial effects and…Abstract Number: 0011 • ACR Convergence 2020
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…Abstract Number: 0359 • ACR Convergence 2020
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…Abstract Number: 0635 • ACR Convergence 2020
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 40
- Next Page »